Sun Enters Japan Through Divested Novartis Portfolio
Another multinational is shedding a portfolio of non-core mature products in Japan to a generics-focused company, as such drugs come under pricing pressure.
Another multinational is shedding a portfolio of non-core mature products in Japan to a generics-focused company, as such drugs come under pricing pressure.